Anti-gonadotrophin releasing hormone antibodies inhibit the growth of MCF7 human breast cancer xenografts by Jacobs, E et al.
Oophorectomy has been the standard first line endocrine therapy
in premenopausal patients with advanced breast cancer over the
past century (Beatson, 1896; Lett, 1905). Initiall y, this was carried
out either by su r gery, or through the use of radiotherap y, both
methods producing an irreversible post-menopausal state. More
recentl y, GnRH agonists (e.g. goserelin) have been reported to
inhibit ovarian function and reduce oestrogen (E2) and proges-
terone to post-menopausal levels ( Williams et al, 1986). The e ffect
is reversible with ovarian function returning to normal on stopping
treatment. This particular point has been used to promote
gonadotrophin releasing hormone (GnRH) analogues not only for
advanced breast cancer where it has been shown to be e ffective
(Blamey et al, 1992), but also as an adjuvant breast cancer therapy
and in benign gynaecological conditions. This paper reports on a
new, potentially reversible, method of inhibiting ovarian function
via anti-GnRH antibodies (Ab), and its e ffect on the in vivo
growth of the hormone-sensitive breast cancer cell line, MCF7.
GnRH Pharmaccine is an immunogen consisting of the GnRH
decapeptide linked through its amino terminus via a 7 amino acid
spacer to diphtheria toxoid (DT). GnRH Pharmaccine has been
shown to induce production of anti-GnRH Ab when injected into
rabbits. This was accompanied by disruption of the normal hypo-
thalamus/pituitary/gonadal axis resulting in the castrate state and
proved to be an e ffective method of contraception (D Michaeli,
personal communication). This alteration of hormonal status
included reduced serum levels of E2 in female, and testosterone in
male, rabbits. The present study was established to determine
whether treatment with anti-GnRH Ab would inhibit the growth of
MCF7 human breast cancer xenografts in a nude mouse model and
to provide information on the mechanisms involved.
MATERIALS AND METHODS
Cell line
The human breast tumour cell line MCF7 was obtained from Dr
John Nelson, Queens Universit y, Belfast. The cell line grown in
vitro in our laboratory was sensitive to E2 and expressed high
levels of both oestrogen (ER) and progesterone receptors (PR).
Receptor levels measured in fmol mg–1 of cytosolic protein by EIA
were: ER – 12 8 ±25; PR – 36 7 ±13 (without E2), the latter rising
to 48 7 ±16 (with E2 supplementation) (Jacobs et al, 1996).
Xenograft tumour
Female nude mice (Harlan-Olac, Biceste r , UK) were maintained in
sterile isolation (Cancer Studies Unit, University of Nottingham)
and used at 6–8 weeks of age. A xenograft was established by
subcutaneous (s.c.) injection of in vitro cultured MCF7 cells into
the flank of mice supplemented with E2. For the first experiment,
the MCF7 xenograft line was maintained in passage by implanting
portions of minced tumour s.c. in E2-supplemented mice, with the
E2 pellets being removed when tumours were palpable and before
treatment started. The MCF7 xenograft line used in subsequent
experiments was maintained in passage by implanting portions of
minced tumour s.c. in mice without E2 supplementation. All
animal work conformed to United Kingdom Co-ordinating
Committee for Cancer Research (UKCCCR) guidelines.
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Anti-GnRH Ab treatment and control groups
1. One group of mice received passive immunization with anti-
GnRH Ab that had previously been raised in rabbits; the
rabbits were immunized with GnRH Pharmaccine to raise anti-
GnRH Ab that was then affinity-purified from the rabbit
serum. Anti-GnRH Ab was given by intraperitoneal (i.p) injec-
tion twice weekly at a dose of 0.35 mg in 0.5 ml 0.9% sodium
chloride (NaCl).
2. Purified rabbit immunoglobulin (IgG) was obtained from
Sigma (Poole, Dorset, UK). The dose given i.p twice weekly
was 0.35 mg IgG in 0.5 ml 0.9% NaCl.
3. 0.9% NaCl (0.5 ml) was given as a control by the same
schedule (i.e. twice weekly i.p.). Pellets were obtained from
Innovative Research of America (Sarasota, FL, USA) and
implanted s.c. in the non-tumour-bearing flank. The pellets
deliver treatments (4–6) by slow release over 60 days and were
replaced when necessary to maintain dosage.
4. Tamoxifen pellets (5.0 mg).
5. Corresponding placebo pellets with the same basic composi-
tion but without the active drug.
6. E2 supplementation (E2 pellet 0.72 mg).
Determination of the effect of treatment on tumour
growth
When xenograft tumours became palpable, the nude mice were
randomized into treatment groups (n = 10 per group) and E2 pellets
removed (Experiment 1). Experiments comparing the four main
treatment groups (anti-GnRH Ab, 0.9% NaCl control, Tamoxifen
pellet, or placebo pellet) were performed three times.
The rationale for the treatment groups was as follows: Anti-
GnRH Ab was evaluated against 0.9% NaCl, representing the
baseline control (vehicle in which antibody was delivered). The
therapeutic effect of anti-GnRH Ab treatment was compared with
tamoxifen, a treatment known to be effective in the treatment of
hormone-sensitive breast cancer given at a dose known to be effec-
tive in this xenograft model (Osborne et al, 1985). Placebo pellets
were used as a control for the tamoxifen-treated group. E2
supplementation was maintained in a fifth group (experiment 1) to
determine the hormone sensitivity of the MCF7 xenograft. In
experiment 3 an additional group was included to assess any non-
specific effects of rabbit IgG on xenograft growth since anti-
GnRH antibodies had been raised in rabbits.
Xenograft tumour size was measured twice weekly by an
independent observer blind to which treatment the mice were
receiving. The tumour size was expressed as the multiplication
product of the two largest perpendicular diameters measured in
mm using callipers. Animals were terminated when xenograft
tumour size (cross-sectional area) exceeded 250 mm2. For each of
the three experiments, mean tumour size was plotted until animals
started to be terminated. The time in days taken for tumour size to
reach 200 mm2 was noted for each animal and these data for the
four treatment groups common to all three experiments (anti-
Table 1 Median time in days from start of treatment: animals bearing
tumours smaller than 200 mm2 cross-sectional area
Treatment Experiment 1 Experiment 2 Experiment 3 Experiments 1–3
E2 14 NT NT NA
0.9% NaCl 31.5 33.3 26.3 29.4
Rabbit IgG NT NT 35.0 NA
Anti-GnRH Ab 77.0 49.0 55.0 71.6
Tamoxifen 44.8a 84.0 56.0 59.4
Placebo 42.0 35.0 35.0 37.7
The median times were derived using Lee–Desu statistics (Lee and Desu,
1972) for individual treatment groups (n = 8–10) within each experiment and
(last column) in a separate analysis for all animals (n = 26–30) in treatment
groups common to all three experiments. aTumour regressed completely in
one animal; NT, not tested; NA, not applicable.
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Figure 1 Experiment 1. The mean cross-sectional area in mm2 (y axis) of MCF7 xenografts in nude mice within each treatment group (n = 10) was plotted
against time in days from start of therapy (x axis) during the period before any mice were terminated. s.e.m. are not shown for clarity. Treatments given were:
0.9% NaCl control (l l), anti-GnRH antibody (l), placebo control (n n), tamoxifen (n) and E2 (- - -)354 E Jacobs et al
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GnRH Ab, 0.9% NaCl, tamoxifen pellet, or placebo pellet) were
combined for analysis.
Assessment of reproductive organs
The uteri with ovaries attached were dissected out and excess fat
removed. The combined weight of ovaries and uterus was deter-
mined for individual animals in each treatment group. The organs
were then fixed in formol calcium, embedded in paraffin wax,
sections were cut through both ovary and uterus and stained with
haematoxylin and eosin (H&E). All histological sections were
examined by a consultant pathologist (IOE) who was not informed
which treatment the mice had been given.
Measurement of E2 and luteinizing hormone serum
concentrations
Serum was collected at 28-day intervals from start of treatment
and also at termination. Samples within treatment groups were
pooled to provide sufficient volumes for analysis. Serum E2 levels
were measured by a sensitive E2 radioimmune assay (Dowsett et
al, 1987). The detection limit of the assay was 3 pM per litre and
the mean CV between 5 and 30 pM per litre was < 7%. Luteinizing
hormone (LH) was measured using a rat LH radioimmunoassay
(RIA) supplied by National Hormone and Pituitary Program
(NIDDK) (anti-rat LH-S-11 antiserum lot# AFP-C697071P, rat
LH-1-9 lot# AFP-10250C, rat LH-RP-3 lot# AFP-7187B).
ER and PR measurement in tumours
ER and PR expression in xenograft tumours from each treatment
group were determined semi-quantitatively by immunocytochem-
ical methods. Paraffin sections for tumours from each treatment
group were fixed and stained for ER using DAKO ID5 anti-ER
monoclonal antibody (DAKO, High Wycombe, Bucks, UK) and
for PR using a rat anti-PR monoclonal antibody (PR-EIA kit 4012;
Abbott, Maidenhead, Berks, UK). The sections were assessed for
ER and PR staining by an independent pathologist (IOE) experi-
enced in human breast pathology. Tumour sections were scored for
percentage of cells staining for ER (or PR) and for the intensity of
the staining. Histochemical scores (H-scores) were calculated
from these two values as previously described (Goulding et al,
1995).
Statistical analysis
The change in size for each xenograft tumour was calculated at
various time points after start of treatment. These data were
analysed by analysis of variance (ANOVA) using repeated
measures. The time in days for xenografts to attain 200mm2 was
used as an end point and compared between treatment groups
using Lee–Desu statistics which are a modification of Gehan’s
generalized Wilcoxon test (Lee and Desu, 1972). Tumours that did
not reach 200mm2 were included in the analysis. Mann–Whitney
analysis was used to compare treatment pairs at certain time points
within each experiment. Mann–Whitney analysis was also used to
analyse reproductive organ weights, H-scores and serum hormone
levels with differences regarded as significant if P< 0.05.
RESULTS
Effect of treatment on tumour growth
The rate of tumour growth was significantly increased by E2
supplementation (P< 0.05) (Figure 1). Rabbit anti-GnRH Ab
inhibited tumour xenograft growth significantly by day 21 of treat-
ment (P< 0.05 by Mann–Whitney and ANOVA) compared to
0.9% NaCl-treated control mice in all three experiments (Figures
1–3) and compared to IgG-treated control mice (experiment 3).
Tumour growth was inhibited significantly in mice treated with
tamoxifen compared to mice bearing placebo pellets in experiment
2 (Mann–Whitney, P< 0.05 at day 28, Figure 2). There was a
Table 2Oestrogen and progesterone receptor expression in MCF7 xenografts
Treatment Experiment ER PR
Cells staining (%) H-score Cells staining( %) H-score
Control (NaCl) 1 70 ±0 75 ±5 20 ±0 45 ±0
2 83 ±8 153 ±11 < 5 0
3 95 ±5 150 ±40 < 5 0
Rabbit IgG 3 100 ±0 190 ±0< 50
Anti-GnRH Ab 1 90 ±0 175 ±5 < 5 2.5 ±2.5
2 95 ±5 205 ±27 < 5 0
3 100 ±0 180 ±0< 50
Tamoxifen 1 0 0 22  ±8 47 ±18
2 58 ±34 95 ±64 26 ±2 53 ±4
3 70 ±10 65 ±15 5 ±0 10 ±0
Placebo 1 60 ±10 75 ±25 25 ±10 52 ±22
2 87 ±5 147 ±33 < 5 8 ±11
3 100 ±0 175 ±5< 50
E2 1 0 0 70 ±0 120 ±0
ER and PR expression was evaluated semi-quantitatively by immunocytochemical methods using receptor-specific monoclonal antibodies. The % of cells
staining positive for each receptor and the H-scores derived by taking into account the intensity of staining (Goulding et al, 1995) are shown. The values given
are the mean ±s.e.m. for 2–4 tumours from each treatment group in separate experiments.GnRH antibody therapy 355
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Figure 3 Experiment 3. Coordinates and plot symbols as in Figure 1, plus treatment with rabbit IgG (+)
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Figure 4 The effect of treatment on tumour growth rate: the percentage of animals with tumours of cross-sectional area < 200 mm2 (y axis) was plotted
at weekly intervals (x axis) pooling data from all three experiments. Symbols: 0.9% NaCl control (l l), anti-GnRH antibody (l), placebo control (n n) and
tamoxifen (n)
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Figure 2 Experiment 2. Coordinates and plot symbols as in Figure 1356 E Jacobs et al
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similar trend in experiment 1 (Figure 1), where one animal treated
with tamoxifen showed complete regression of tumour growth.
There was no difference between tamoxifen and placebo groups in
experiment 3 (Figure 3) during the 3 weeks before any mice were
terminated.
The effect of treatments on tumour growth over a longer time
period was analysed further. Median times taken for tumours to
reach 200 mm2 in each of the treatment groups within individual
experiments are shown (Table 1, columns 1–3). Median times
(taken for tumours to reach 200 mm2) were greater in treated
animals than in controls (anti-GnRH Ab vs 0.9% NaCl and tamox-
ifen vs placebo). Data for these four groups in all three experi-
ments were combined and are described below. The median time
for tumours to reach 200 mm2 in animals treated with IgG (experi-
ment 3) was 35 days (Table 1). This was not significantly different
from the results in 0.9% NaCl control groups (26.3–33.3 days). In
Figure 5 Reproductive organs: sections stained with haematoxylin and eosin from control animals (A, B), from those treated with anti-GnRH Ab (C, D) and
tamoxifen (E, F). Uteri (B, D, F) were photographed at double the magnification used for ovaries (A, C, D)
A
C
E F
D
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comparison, the median time for tumours to reach 200 mm2 in the
E2-supplemented group (experiment 1) was just 14 days. This was
significantly faster than for 0.9% NaCl and placebo control
groups in the same experiment (31.5 days, P = 0.004 and 42 days,
P = 0.006 respectively).
Data for all animals in the four treatment groups common to
the three experiments (anti-GnRH Ab, 0.9% NaCl, tamoxifen,
placebo) were combined. The proportion of animals with tumours
smaller than 200 mm2 was plotted against time (Figure 4) and the
median times to this event are shown (Table 1, column 4). The
median times were 71.6 days for anti-GnRH Ab, 29.4 days for
0.9% NaCl, 59.4 days for tamoxifen and 37.7 days for placebo.
The median time taken for tumours to reach 200 mm2 was signifi-
cantly longer with anti-GnRH Ab treatment than for 0.9% NaCl
controls (P = 0.0002). Tamoxifen treatment compared with
placebo controls was not significant, though the median time with
tamoxifen treatment was significantly longer than that for 0.9%
NaCl controls (P = 0.037). There was no significant difference
between anti-GnRH Ab treatment and tamoxifen.
ER and PR in tumours
Nuclear staining of tumour cells for ER or PR was noted similar to
that seen in human primary tumours. Epithelial tumour cells were
scored for ER or PR staining and there was no staining with a
negative control antibody. Mean H-scores for ER and PR expres-
sion in tumours from the three experiments are shown in Table 2.
Tumours within each treatment group appeared similar, but there
were differences in the levels of receptor expression between
different treatment groups.
ER expression was evident in most tumours in keeping with the
fact that MCF7 is known to express ER. H-scores were higher in
anti-GnRH Ab-treated tumours than 0.9% NaCl controls (P =
0.007). ER expression was absent in the tumours of mice that
received E2 supplementation. In the first experiment, tumours
treated with tamoxifen did not express ER. In two subsequent
experiments, there was a non-significant trend (P = 0.07) towards
lower ER expression in tumours treated with tamoxifen compared
with controls.
PR expression was highest in tumours where E2 supplementa-
tion had continued, with 70% of cells exhibiting moderate to
intense staining. In tumours from mice not receiving E2 supple-
mentation, H-scores were much lower for PR expression (than for
ER) with very few tumour cells staining with variable intensity. In
the first experiment, PR were expressed by most tumours, but
levels were reduced by anti-GnRH Ab treatment. In the other two
experiments, PR levels were very low in both anti-GnRH Ab and
control groups. There was a trend towards elevation of PR levels
in tumours treated with tamoxifen (P = 0.08).
There was correlation of serum E2 concentrations with PR levels,
and inverse correlation of ER with PR (Spearman’s r rank correla-
tion coefficients of 0.791 and –0.813 respectively, both P < 0.001).
Effect of treatment on the reproductive organs
Organ weights
Weights of the reproductive organs (ovaries and uteri) were in a
similar range for 0.9% NaCl, placebo and IgG control animals
(data not shown). For this reason these data were combined
(median 90 mg, IQ range 70–138, n = 29). In mice treated with
anti-GnRH Ab (n = 18), the reproductive organs weighed signifi-
cantly less than those in controls (median 40 mg, IQ range 33–
50 mg, Mann–Whitney P < 0.001). Organs from tamoxifen-treated
animals (n = 10) were significantly heavier than those from
controls (median 119 mg, IQ range 105–212 mg, Mann–Whitney
P = 0.034).
Histology
Examination of H&E-stained sections (Figure 5) of paraffin-
fixed material from animals in the control groups revealed normal
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per liter (y axis) in serum pooled for animals (n = 10) within each treatment
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Figure 7 LH serum levels were measured in serum pooled from animals
(n = 10) within each treatment group and expressed as a percentage of that
in controls (100%). The graph shows mean % ± s.e.m. for three experiments
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British Journal of Cancer (1999) 80(3/4), 352–359 © Cancer Research Campaign 1999
follicular development and luteinization in ovaries together with
normal endometrial development of glandular structures and
active stroma in uteri. Ovaries and uteri from the anti-GnRH Ab-
treated mice were approximately half the size of those in
controls and exhibited reduced follicular development and non-
luteinized stroma in the ovaries and atrophy of the uteri with fewer
glandular components and inactive stroma. In tamoxifen-treated
animals, ovaries showed follicular development with minimal/
variable luteinization and gross benign cystic hyperplasia of the
endometrium.
Serum E2
The concentration of E2 in serum from treated and control animals
was measured by RIA (Figure 6). Basal E2 levels of 23.7 ± 1.8 and
23.0 ± 6.7 pM per litre were recorded for 0.9% NaCl and placebo
controls respectively. Serum E2 levels were in excess of 900 pM
per litre in E2-supplemented animals, but fell to basal levels
1 week following removal of the pellet (data not shown). E2 serum
levels were significantly reduced by anti-GnRH Ab treatment
(5.9 ± 1.7 pM per litre) in comparison with both 0.9% NaCl and
placebo control groups (both P = 0.04). Rabbit IgG reduced serum
E2 to a level intermediate between anti-GnRH Ab treatment and
0.9% NaCl controls in the one experiment where it was included as
a control (8.5 pM per litre). E2 serum levels in tamoxifen-treated
animals (17.0 ± 5.5 pM per litre) were not significantly different
from those in controls.
Serum LH
Serum LH measurements were within a range of 0.2–3.0 ng ml–1
and are expressed as a percentage of LH measured in the serum of
0.9% NaCl-treated control animals (Figure 7.). LH was signifi-
cantly reduced to 53 ± 14% (P = 0.04) in anti-GnRH Ab-treated
animals compared with controls. Serum LH levels were similar in
tamoxifen-treated animals and controls.
Toxicity
Treatments were well-tolerated without signs of toxicity. Weight
loss was more pronounced in some mice after prolonged treatment
with tamoxifen, in 3/29 cases necessitating termination before
tumours had attained the target size. However, there was no signif-
icant difference in the overall weights of mice in different treat-
ment groups.
DISCUSSION
The growth of MCF7 human breast tumour xenografts in nude
mice was significantly inhibited by treatment with anti-GnRH
antibodies compared to controls. Tamoxifen also significantly
inhibited tumour growth compared to 0.9% NaCl controls (Figure
4) but was not statistically different from placebo controls within
the time scale of these experiments. These results parallel work by
other groups using the nude mouse model who have demonstrated
tamoxifen to be tumoristatic rather than tumoricidal on the growth
of MCF7 xenografts (Osborne et al, 1985; Gottardis et al, 1988). In
animals treated with anti-GnRH antibodies, the time taken for
tumours to reach a target size (200 mm2) was longer than in those
given tamoxifen (71 vs 59 days respectively). Whilst there was no
significant difference between these two groups, the result shows
that anti-GnRH Ab were at least as effective as the anti-oestrogen,
tamoxifen in slowing the growth of established tumours at the
dosages used in this study.
Agonists and antagonists of luteinizing hormone releasing
hormone (LHRH) have been shown to be inhibitory to the growth
of MCF7-MIII xenografts, and to reduce serum levels of both E2
and LH in treated animals (Yano et al, 1992). Passive infusion of
anti-GnRH Ab had a similar effect resulting in suppression of
serum E2 to very low levels, and also reducing serum LH levels
compared to those in controls. The GnRH agonist, goserelin, is
known to reduce follicle-stimulating hormone (FSH) and LH
levels in premenopausal patients with breast cancer, with conse-
quent reduction of E2 and progesterone to castrate levels (Williams
et al, 1986; Blamey et al, 1992). In the present study, passive
immunization of mice with anti-GnRH Ab appeared to cause
similar suppression of the pituitary ovarian axis.
Further evidence for suppression of pituitary gonadal function
by anti-GnRH antibodies was the reduced ovary/uterine weights
and the histological findings indicating lack of follicular develop-
ment, no luteinization of the ovaries and inactive endometrium.
The ovarian changes reported in this study, in anti-GnRH Ab-
treated mice, are similar to those previously reported in breast
cancer patients treated with the GnRH analogue, goserelin
(Zoladex) (Williamson et al, 1988), their two major observations
being lack of corporus luteum and increased frequency of cysts
indicative of atretic Graafian follicles.
Chemical oophorectomy (e.g. goserelin) in premenopausal
patients reduces the level of circulating E2 compared to that found
in post-menopausal patients and is able to induce therapeutic
remissions (Williams et al, 1986; Blamey et al, 1992). MCF7
tumour xenografts treated with anti-GnRH Ab appeared to respond
to reduced E2 availability by up-regulation of ER and down-regu-
lation of PR. These findings are in keeping with previous literature
on the effect of E2 on steroid hormone receptors in normal tissues
and in MCF7 breast cancer cells (Kraus and Katzenellenbogen,
1993; Cho et al, 1994). Anti-GnRH Ab were not directly inhibitory
to MCF7 tumour cell proliferation in vitro (data not shown),
supporting an indirect mechanism in vivo as the most likely expla-
nation of the tumour inhibitory effects of anti-GnRH antibodies.
A recent report has shown anti-GnRH immunization to be effec-
tive against mammary cancer in a rat syngeneic model (Ferro and
Stimpson, 1997). We have shown the strategy can also be effective
against a human breast cancer.
To summarize, this study has shown that passive immunization
with anti-GnRH Ab in nude mice resulted in reduced levels of
circulating E2. This supports evidence from studies in rabbits
where active immunization with the GnRH immunogen (GnRH
Pharmaccine) resulted in castrate levels of sex hormones and
effective contraception. GnRH Pharmaccine appears to be a novel
method of producing a castrate state. In this study, anti-GnRH Ab
showed enhanced therapeutic efficacy on the growth of a breast
tumour xenograft comparable with tamoxifen, which is the current
anti-oestrogen of choice as first-line endocrine therapy in post-
menopausal patients with breast cancer.
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